Months af­ter team­ing up on RTK in­hibitor Lenvi­ma, Ei­sai/Mer­ck win new FDA OK in liv­er can­cer

Ei­sai’s star can­cer drug Lenvi­ma — the sub­ject of a re­cent $300 mil­lion pact with Mer­ck — just got the green light from reg­u­la­tors to treat a new in­di­ca­tion in liv­er can­cer.

The drug, whose gener­ic name is lenva­tinib, was al­ready ap­proved by the FDA in 2015 to treat thy­roid can­cer, and in 2016 it won ap­proval for re­nal cell car­ci­no­ma. But the med has been lined up to take a shot at sev­er­al new in­di­ca­tions, in­clud­ing this lat­est OK in he­pa­to­cel­lu­lar car­ci­no­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.